Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
30.11.2018 12:54:07

DGAP-PVR: STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: STADA Arzneimittel AG
STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

30.11.2018 / 12:54
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: STADA Arzneimittel AG
Street: Stadastraße 2-18
Postal code: 61118
City: Bad Vilbel
Germany
Legal Entity Identifier (LEI): 529900FMTTLMH0P0DL10

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Legal entity: Cinven Capital Management (VI) General Partner Limited
City of registered office, country: Saint Peter Port, Guernsey, Channel Islands

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Nidda Healthcare GmbH

5. Date on which threshold was crossed or reached:
28 Nov 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 93.67 % 0.004 % 93.67 % 62,342,440
Previous notification 65.31 % 0.0008 % 65.31 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0007251803 58,398,885 % 93.67 %
Total 58,398,885 93.67 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Tender under domination and profit and loss transfer agreement n/a n/a 2,627 0.004 %
    Total 2,627 0.004 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 1) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 93.67 % % 93.67 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 2) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 93.67 % % 93.67 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 3) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 93.67 % % 93.67 %
 
Cinven Capital Management (VI) General Partner Limited % % %
Cinven Capital Management (VI) Limited Partnership Incorporated % % %
Sixth Cinven Fund (No. 4) Limited Partnership % % %
Ciddan S.à r.l. % % %
Nidda Topco S.à r.l. % % %
Nidda Midco S.à r.l. % % %
Nidda German Topco GmbH % % %
Nidda German Midco GmbH % % %
Nidda BondCo GmbH % % %
Nidda Healthcare Holding GmbH % % %
Nidda Healthcare GmbH 93.67 % % 93.67 %
 

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
29 Nov 2018



30.11.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Internet: www.stada.de

 
End of News DGAP News Service

753171  30.11.2018 

fncls.ssp?fn=show_t_gif&application_id=753171&application_name=news&site_id=smarthouse

Analysen zu STADAmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!